(NASDAQ: INMB) Inmune Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.92%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.93%.
Inmune Bio's earnings in 2025 is -$49,887,000.On average, 8 Wall Street analysts forecast INMB's earnings for 2025 to be -$42,140,292, with the lowest INMB earnings forecast at -$53,409,783, and the highest INMB earnings forecast at -$33,776,570. On average, 8 Wall Street analysts forecast INMB's earnings for 2026 to be -$38,415,698, with the lowest INMB earnings forecast at -$66,697,095, and the highest INMB earnings forecast at -$20,098,455.
In 2027, INMB is forecast to generate -$32,947,110 in earnings, with the lowest earnings forecast at -$44,291,040 and the highest earnings forecast at -$14,236,406.